Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
0.7729 x 10 0.7979 x 10
Pre-market by (Cboe BZX)
0.7628 -0.0221 (-2.82%) 02/18/25 [NASDAQ]
0.7729 x 10 0.7979 x 10
Pre-market 0.7900 +0.0272 (+3.57%) 08:04 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7511
Day High
0.9744
Open 0.8700
Previous Close 0.7849 0.7849
Volume 8,937,101 8,937,101
Avg Vol 4,837,000 4,837,000
Stochastic %K 27.98% 27.98%
Weighted Alpha -66.06 -66.06
5-Day Change +0.0120 (+1.60%) +0.0120 (+1.60%)
52-Week Range 0.6204 - 3.2600 0.6204 - 3.2600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,830
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -177,120 K
  • EBIT $ -211 M
  • EBITDA $ -209 M
  • 60-Month Beta 1.04
  • Price/Sales 42.43
  • Price/Cash Flow N/A
  • Price/Book 1.02
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings $-0.18 on 11/12/24
  • Next Earnings Date 03/10/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 356.65% ( +39.15%)
  • Historical Volatility 106.35%
  • IV Percentile 98%
  • IV Rank 91.79%
  • IV High 385.65% on 02/11/25
  • IV Low 32.53% on 08/20/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 3,493
  • Volume Avg (30-Day) 4,063
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 71,817
  • Open Int (30-Day) 55,142

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.16
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +45.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6600 +15.58%
on 02/12/25
Period Open: 0.6900
1.0900 -30.02%
on 01/24/25
+0.0728 (+10.55%)
since 01/17/25
3-Month
0.6204 +22.95%
on 12/05/24
Period Open: 0.9050
1.0900 -30.02%
on 01/24/25
-0.1422 (-15.71%)
since 11/18/24
52-Week
0.6204 +22.95%
on 12/05/24
Period Open: 3.1800
3.2600 -76.60%
on 02/20/24
-2.4172 (-76.01%)
since 02/16/24

Most Recent Stories

More News
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

LXRX : 0.7628 (-2.82%)
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

LXRX : 0.7628 (-2.82%)
Lexicon Appoints Scott Coiante as Chief Financial Officer

LXRX : 0.7628 (-2.82%)
Lexicon Announces Receipt of Complete Response Letter for Zynquistaâ„¢ (sotagliflozin)

LXRX : 0.7628 (-2.82%)
2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

LXRX : 0.7628 (-2.82%)
VTRS : 10.86 (+0.56%)
TEVA : 16.57 (+1.97%)
AMGN : 292.80 (+0.56%)
PFE : 25.56 (+0.12%)
Lexicon Pharmaceuticals Completes Patient Enrollment for PROGRESS Study of LX9211, Exceeding Targets by 20%

Lexicon Pharmaceuticals exceeded enrollment targets in its PROGRESS study of LX9211 for diabetic peripheral neuropathic pain, aiming for Q1 2025 data.Quiver AI SummaryLexicon Pharmaceuticals announced...

LXRX : 0.7628 (-2.82%)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

LXRX : 0.7628 (-2.82%)
Lexicon Pharmaceuticals to Participate in December Investor Conferences

LXRX : 0.7628 (-2.82%)
Lexicon Pharmaceuticals Announces Strategic Restructuring to Focus on R&D and Cut Operating Costs by $100 Million

Lexicon Pharmaceuticals is restructuring to eliminate commercial operations, focusing on R&D, expecting $100 million in cost savings by 2025.Quiver AI SummaryLexicon Pharmaceuticals, Inc. has announced...

LXRX : 0.7628 (-2.82%)
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

LXRX : 0.7628 (-2.82%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.1311
2nd Resistance Point 1.0527
1st Resistance Point 0.9078
Last Price 0.7628
1st Support Level 0.6845
2nd Support Level 0.6061
3rd Support Level 0.4612

See More

52-Week High 3.2600
Fibonacci 61.8% 2.2517
Fibonacci 50% 1.9402
Fibonacci 38.2% 1.6287
Last Price 0.7628
52-Week Low 0.6204

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion